MacroGenics, Inc.
NASDAQ:MGNXBiotechnology
+$0.08 today
- Market cap
- $126.54M
- Beta
- 1.20
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$1.11
Volume 0.93M
Average 0.98M
Dividends
MacroGenics, Inc. dividends
Review the payout history, yield, and how well earnings and cash flow support the dividend.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Competitor dividends
How does MacroGenics, Inc. compare as an income stock?
Compare dividend yield, payout ratios, and buybacks with similar companies.
Competitor Dividends
Peer payout, dividend, and buyback comparison
| Company | Market Cap | Dividend Yield | Annual Dividend | Payout Ratio | Buyback Yield |
|---|---|---|---|---|---|
Ovid Therapeutics Inc. NASDAQ:OVID | $479.38M | 0.00% | $0.00 | 0.00% | 0.00% |
Shattuck Labs, Inc. NASDAQ:STTK | $473.57M | 0.00% | $0.00 | 0.00% | 0.00% |
Whitehawk Therapeutics Inc NASDAQ:WHWK | $180.57M | 0.00% | $0.00 | 0.00% | 0.00% |
InflaRx N.V. NASDAQ:IFRX | $172.42M | 0.00% | $0.00 | 0.00% | 0.00% |
Zentalis Pharmaceuticals, Inc. NASDAQ:ZNTL | $167.05M | 0.00% | $0.00 | 0.00% | 0.00% |
Oramed Pharmaceuticals Inc. NASDAQ:ORMP | $154.33M | 6.54% | $0.25 | 0.00% | 2.98% |
Coya Therapeutics, Inc. NASDAQ:COYA | $73.42M | 0.00% | $0.00 | 0.00% | 0.00% |
Clene Inc. NASDAQ:CLNN | $56.45M | 0.00% | $0.00 | 0.00% | 0.00% |
Connect Biopharma Holdings Limited NASDAQ:CNTB | $42.65M | 0.00% | $0.00 | 0.00% | 0.00% |
Context Therapeutics Inc. NASDAQ:CNTX | $16.61M | 0.00% | $0.00 | 0.00% | 0.00% |
Questions
Dividend questions
Common questions about MGNX's dividend, answered from reported figures.
Does MGNX stock pay dividends?
MacroGenics, Inc. (MGNX) currently pays a dividend. The indicated dividend per share is 0.00 USD and the dividend yield is 0.00%.
Is MGNX's dividend covered?
The payout ratio is 0.0%, so compare that against earnings and free cash flow before relying on the dividend.
Continue the stock analysis
Jump to another research area for this company.